Division of Oncology/Hematology, New York Medical College and Westchester Medical Center, Valhalla, NY, 10595, USA.
Exp Hematol Oncol. 2012 Jun 18;1(1):14. doi: 10.1186/2162-3619-1-14.
Stromal or mesenchymal neoplasms affecting the gastrointestinal (GI) tract have undergone a remarkable evolution in how they are perceived, classified, approached, diagnosed and managed over the last 30 years. Gastrointestinal stromal tumors (GIST) account for approximately 1% to 3% of all malignant GI tumors. The clinical features can vary depending on the anatomic location, size and aggressiveness of the tumor. Metastatic GIST represents a successful example of molecular targeted therapy. In this comprehensive review, we discuss the epidemiology, clinical features and diagnostic modalities for GIST. We also describe treatment options for early stage, locally advanced and metastatic GIST. Indications for neoadjuvant and adjuvant therapy along with duration of therapy are also explained. A brief discussion of latest biomarkers and updates from recent meetings is also provided.
在过去的 30 年中，影响胃肠道（GI）的基质或间质肿瘤在其认知、分类、处理、诊断和管理方式上发生了显著的变化。胃肠道间质瘤（GIST）约占所有恶性 GI 肿瘤的 1%至 3%。临床特征可根据肿瘤的解剖位置、大小和侵袭性而有所不同。转移性 GIST 是分子靶向治疗的成功范例。在这篇全面的综述中，我们讨论了 GIST 的流行病学、临床特征和诊断方法。我们还描述了早期、局部晚期和转移性 GIST 的治疗选择。还解释了新辅助和辅助治疗的适应证以及治疗持续时间。简要讨论了最新的生物标志物和最近会议的更新。
